Name | Title | Contact Details |
---|---|---|
Jamie Kitano |
Director, Corporate Counsel | Profile |
Christopher Thompson |
SR VP Sales, Access, Govt Affairs | Profile |
Chris Slavinsky |
Chief Business and Legal Officer | Profile |
Thomas Fitzpatrick |
Chief Legal Officer | Profile |
Evommune is a clinical stage biotechnology company dedicated to the development of transformative medicines for inflammatory diseases. We are leveraging our innovative, tissue-based approach to advance insights and accelerate the development of these transformative therapies. Evommune is led by a successful and experienced leadership team focused on building a robust pipeline of unique therapies that help patients with chronic inflammatory diseases.
Nuvalent is creating precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs.
NexBio is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Gliknik Inc., a biopharmaceuticals company, develops therapies for patients with cancer and immune disorders.
Entegrion is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.